Related Experiment Video
Updated: Mar 1, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Safety and efficacy of catheter-based left atrial appendage closure in patients with contraindications for long-term
Adrian Seidel1, Abdul S Parwani2, Florian Krackhardt2
1Department of Cardiology, Campus Virchow-Klinikum, Charité University of Medicine, Berlin, Germany - adrian.seidel@charite.de.
Insights
Percutaneous left atrial appendage closure (LAAC) effectively prevents thromboembolisms in high-risk patients. However, major bleeding events occurred frequently, regardless of anticoagulation status post-procedure.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Percutaneous left atrial appendage closure (LAAC) is an alternative for patients with non-rheumatic atrial fibrillation at high risk for stroke.
- The optimal post-procedural antithrombotic therapy remains controversial.
Purpose of the Study:
- To evaluate the efficacy and safety of LAAC in patients with non-rheumatic atrial fibrillation, high thromboembolic risk, and contraindications for long-term anticoagulation.
Main Methods:
- A total of 118 patients underwent attempted LAAC between 2010-2015.
- Successful device implantation was achieved in 95% of cases.
- Patients received either anticoagulation or dual antiplatelet therapy (DAPT) post-procedure, with potential reduction based on follow-up imaging.
Main Results:
- The procedural complication rate was 3.4%.
- One transient ischemic attack (TIA) occurred during follow-up (0.6%/year).
- Eleven major bleeding events (6.6%/year) were observed, occurring in patients on various antithrombotic regimens, including DAPT and aspirin alone.
Conclusions:
- Catheter-based LAAC demonstrates high efficacy in preventing thromboembolic events.
- Major bleeding complications are common following LAAC, irrespective of the antithrombotic strategy employed.
Background:
Percutaneous left atrial appendage closure (LAAC) and the role of postinterventional anticoagulation often evokes controversy in daily practice. This study aimed to evaluate LAAC in patients with non-rheumatic atrial fibrillation, high thromboembolic risk and contraindications for long-term anticoagulation in a clinical scenario.
Methods:
Between 2010-2015, LAAC was attempted in 118 patients (47 women).
Results:
Devices were successfully implanted in 95% (Watchman™ device: N.=97; Amplatzer™ Cardiac Plug/Amulet: N.=14; Amplatzer PFO Occluder: N.=1). Mean age was 75±8.35 years. Mean HAS-BLED and CHA2DS2VASc scores were 4.3 and 4.9, respectively. Median follow-up was 447 days (IQR: 183-789 days). The primary safety endpoint was defined as major bleeding according to the International Society on Thrombosis and Hemostasis. The combined efficacy endpoint included ischemic strokes, transitory ischemic attacks (TIA) and systemic embolisms. Procedural complication rate was 3.4%. After successful intervention, either a therapy with anticoagulants (N.=62) or dual antiplatelet therapy (DAPT, N.=50) was prescribed temporarily. Medication was reduced if implantation proved satisfying in a 6-week follow-up transesophageal echocardiography, which was the case in 79% of these patients. During follow-up, one patient suffered a TIA (0.6%/year). No other efficacy event was observed. Eleven major bleedings occurred (6.6%/year): one each under DAPT plus phenprocoumon, DAPT plus rivaroxaban, acetylsalicylic acid (ASA) plus rivaroxaban, two under DAPT, two under ASA plus low molecular weight heparin, and four under ASA only.
Conclusions:
In the present study, catheter-based LAA occlusion prevented thromboembolisms with high efficacy. Major bleedings were however common in patients with, but also without anticoagulation, independent from time course.
Related Concept Videos
Cardiac Catheterization III: Left Heart Catheterization
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization II: Right Heart Catheterization
Venous Thrombosis III: Interprofessional Care
Cardiac Catheterization IV: Nursing Management

